Amplitude Surgical
Market Cap
€79.2m
Last Updated
2020/06/06 00:07 UTC
Data Sources
Company Financials +
Executive Summary
Amplitude Surgical SA develops and markets products for orthopedic surgery.
Rewards
PE ratio (22.5x) is below the Medical Equipment industry average (47.3x)
Risk Analysis
Earnings are forecast to decline by an average of -158.3% per year for the next 3 years
+ 1 more risk
Snowflake Analysis
Slightly overvalued with questionable track record.
Similar Companies
Share Price & News
How has Amplitude Surgical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMPLI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
36.1%
AMPLI
-11.5%
FR Medical Equipment
8.7%
FR Market
1 Year Return
-28.8%
AMPLI
42.8%
FR Medical Equipment
-2.4%
FR Market
Return vs Industry: AMPLI underperformed the French Medical Equipment industry which returned 47.4% over the past year.
Return vs Market: AMPLI underperformed the French Market which returned -3.8% over the past year.
Shareholder returns
| AMPLI | Industry | Market | |
|---|---|---|---|
| 7 Day | 36.1% | -11.5% | 8.7% |
| 30 Day | 30.7% | -1.9% | 15.9% |
| 90 Day | 20.3% | 35.6% | 1.3% |
| 1 Year | -28.8%-28.8% | 42.8%42.8% | -0.7%-2.4% |
| 3 Year | -61.8%-61.8% | 43.9%42.1% | 11.2%2.2% |
| 5 Year | n/a | 144.9%139.2% | 31.1%14.3% |
Price Volatility Vs. Market
How volatile is Amplitude Surgical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
If You Had Bought Amplitude Surgical (EPA:AMPLI) Stock Three Years Ago, You'd Be Sitting On A 74% Loss, Today2 months ago | Simply Wall St
Does Amplitude Surgical (EPA:AMPLI) Have A Healthy Balance Sheet?3 months ago | Simply Wall St
Could The Amplitude Surgical SA (EPA:AMPLI) Ownership Structure Tell Us Something Useful?Valuation
Is Amplitude Surgical undervalued compared to its fair value and its price relative to the market?
22.46x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AMPLI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AMPLI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AMPLI is good value based on its PE Ratio (22.5x) compared to the Medical Equipment industry average (47.3x).
PE vs Market: AMPLI is poor value based on its PE Ratio (22.5x) compared to the French market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: AMPLI's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: AMPLI is good value based on its PB Ratio (0.9x) compared to the FR Medical Equipment industry average (2.6x).
Next Steps
Future Growth
How is Amplitude Surgical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-158.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMPLI's earnings are forecast to decline over the next 3 years (-158.3% per year).
Earnings vs Market: AMPLI's earnings are forecast to decline over the next 3 years (-158.3% per year).
High Growth Earnings: AMPLI's earnings are forecast to decline over the next 3 years.
Revenue vs Market: AMPLI's revenue (1.1% per year) is forecast to grow slower than the French market (3.9% per year).
High Growth Revenue: AMPLI's revenue (1.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMPLI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Amplitude Surgical performed over the past 5 years?
13.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMPLI has a large one-off gain of €5.6M impacting its December 31 2019 financial results.
Growing Profit Margin: AMPLI became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AMPLI has become profitable over the past 5 years, growing earnings by 13.5% per year.
Accelerating Growth: AMPLI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AMPLI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.8%).
Return on Equity
High ROE: AMPLI's Return on Equity (3.4%) is considered low.
Next Steps
Financial Health
How is Amplitude Surgical's financial position?
Financial Position Analysis
Short Term Liabilities: AMPLI's short term assets (€82.3M) exceed its short term liabilities (€37.5M).
Long Term Liabilities: AMPLI's short term assets (€82.3M) do not cover its long term liabilities (€148.7M).
Debt to Equity History and Analysis
Debt Level: AMPLI's debt to equity ratio (118.6%) is considered high.
Reducing Debt: AMPLI's debt to equity ratio has reduced from 971.2% to 118.6% over the past 5 years.
Debt Coverage: AMPLI's debt is not well covered by operating cash flow (15.5%).
Interest Coverage: AMPLI's interest payments on its debt are not well covered by EBIT (0.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Amplitude Surgical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMPLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMPLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMPLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMPLI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMPLI's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Olivier Jallabert (51yo)
5yrs
Tenure
€2,093,017
Compensation
Mr. Olivier Jallabert is the Founder of Amplitude Surgical SA and serves as its Chairman and has been its Chief Executive Officer since June 10, 2015. Mr. Jallabert is the Founder, Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: Olivier's total compensation ($USD2.37M) is above average for companies of similar size in the French market ($USD326.62K).
Compensation vs Earnings: Olivier's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5yrs | €2.09m | 10.4% €8.2m | |
| CFO & Vice Chairman of Finance | no data | no data | no data | |
| Chief Operating Officer | 1.67yrs | no data | no data | |
| Technical Director | 2.08yrs | no data | no data | |
| Vice President of Marketing & Sales | 1.42yrs | no data | no data | |
| Human Resources Director | 2.08yrs | no data | no data |
2.1yrs
Average Tenure
Experienced Management: AMPLI's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5yrs | €2.09m | 10.4% €8.2m | |
| Director | 5yrs | no data | no data | |
| Independent Director | 5yrs | no data | no data | |
| Director | 5yrs | no data | no data |
5.0yrs
Average Tenure
55yo
Average Age
Experienced Board: AMPLI's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Amplitude Surgical SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amplitude Surgical SA
- Ticker: AMPLI
- Exchange: ENXTPA
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €79.231m
- Shares outstanding: 47.73m
- Website: https://www.amplitude-surgical.com
Number of Employees
Location
- Amplitude Surgical SA
- 11, Cours Jacques Offenbach
- Valence
- Rhône-Alpes
- 26000
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AMPLI | ENXTPA (Euronext Paris) | Yes | Common Stock | FR | EUR | Jun 2015 |
| AMPLIp | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | EUR | Jun 2015 |
| 0RAF | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Jun 2015 |
Biography
Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle. The company also provides AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and the E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, its products include KNEEMAP systems for the measurement of knee kinematics; and instruments for fitting implants. The company sells its products through a network of distributors and agents in approximately 30 countries. It serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 00:07 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.